Business Context and Reporting Period
Company: Baxter International Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2005
Business Overview: Baxter operates in three primary segments: Medication Delivery (IV solutions, infusion systems, anesthesia), BioScience (biopharmaceuticals, plasma proteins, transfusion therapies), and Renal (dialysis products and services). The company is headquartered in Deerfield, Illinois.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended Sep 30, 2005 | 9 Months Ended Sep 30, 2005 | 3 Months Ended Sep 30, 2004 | 9 Months Ended Sep 30, 2004 |
|---|---|---|---|---|
| Net Sales | $2,398 | $7,358 | $2,320 | $6,908 |
| Net Income | $116 | $664 | $276 | $282 |
| Income from Continuing Ops | $116 | $664 | $259 | $277 |
| Diluted EPS (Continuing Ops) | $0.18 | $1.06 | $0.42 | $0.45 |
| Cash and Equivalents | $1,712 (Sep 30, 2005) | N/A | ||
| Operating Cash Flow (9 Months) | $1,314 | $546 | ||
| Gross Margin | 42.1% | 42.0% | 41.5% | 40.5% |
Debt and Liquidity: Total current liabilities were $4,271 million. Long-term debt and lease obligations totaled $3,008 million. The company maintained $1.7 billion in cash and equivalents and $2.0 billion in revolving credit facilities. The net-debt-to-capital ratio was 25.3%.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 3% in the quarter and 7% year-to-date compared to 2004. International sales grew 9% in the quarter and 11% year-to-date, aided by a weaker U.S. dollar.
- Profitability: Net income for the quarter declined 58% compared to the prior year ($116M vs. $276M), primarily due to a $163 million tax charge related to foreign earnings repatriation and significant product charges. However, year-to-date net income increased 135% ($664M vs. $282M) due to a $543 million restructuring charge in the prior year that was not repeated in 2005.
- Segment Performance:
- Medication Delivery: Sales declined 3% in the quarter due to a voluntary hold on COLLEAGUE infusion pump shipments. Pre-tax income dropped 12%.
- BioScience: Sales increased 12% in the quarter, driven by strong demand for recombinant Factor VIII products (ADVATE). Pre-tax income rose 39%.
- Renal: Sales increased 1% in the quarter. Pre-tax income fell 29% due to a $28 million charge for exiting hemodialysis instrument manufacturing.
- Restructuring Benefits: The company recorded a $109 million pre-tax benefit from restructuring adjustments in the first nine months of 2005, reflecting lower-than-expected severance costs.
Guidance, Outlook, Risks, and Unusual Items
Unusual Items and Charges
- COLLEAGUE Infusion Pump Charge: A $77 million pre-tax charge was recorded in Q2 2005 for costs to remediate design issues. The FDA classified related notices as Class I recalls. Shipments of new pumps were halted in July 2005, and the FDA seized approximately 6,000 pumps in October 2005.
- Hemodialysis Exit Charge: A $28 million pre-tax charge was recorded in Q3 2005 to discontinue manufacturing of HD instruments. Total exit costs are estimated at $50 million.
- Tax Repatriation: A $163 million income tax expense was recorded in Q3 2005 associated with the repatriation of approximately $2 billion in foreign earnings under the American Jobs Creation Act of 2004.
Outlook and Guidance
- Restructuring Savings: Management projects the 2004 restructuring program will yield savings of $0.20 to $0.25 per diluted share for full-year 2005. Once fully implemented in 2006, total annual savings are expected to be $0.30 to $0.35 per share.
- Effective Tax Rate: The company lowered its full-year 2005 projected effective tax rate to 21.5%, excluding discrete items like the repatriation charge.
- Capital Expenditures: Management expects to spend approximately $500 million in capital expenditures for full-year 2005.
Risks and Contingencies
- Product Liability: Ongoing litigation regarding mammary implants, plasma-based therapies (HIV/Hepatitis C claims), and vaccines (thimerosal/autism claims). The company believes insurance covers a substantial portion of these liabilities.
- Regulatory Actions: Continued FDA scrutiny regarding the COLLEAGUE pump, including potential injunctions or monetary sanctions.
- Legal Proceedings: Various securities class actions and investigations by the SEC regarding financial restatements and guidance revisions.
Investor Verification Checklist
- COLLEAGUE Pump Resolution: Verify the timeline for resolving design issues, the status of FDA seizures, and potential for additional charges beyond the initial $77 million.
- Repatriation Cash Flow: Confirm the actual cash outflow for the $163 million tax charge and the utilization of repatriated funds for debt reduction and pension contributions.
- Restructuring Progress: Monitor the realization of projected cost savings ($0.20-$0.25/share) and the finalization of the 2004 restructuring program.
- BioScience Growth Sustainability: Assess the durability of sales growth in the BioScience segment, specifically the adoption rate of ADVATE and the impact of the new American Red Cross agreement.
- Legal Reserves: Review updates on mammary implant and plasma therapy litigation reserves to ensure they remain adequate given the volume of pending claims.